Last reviewed · How we verify
PGV-001
At a glance
| Generic name | PGV-001 |
|---|---|
| Sponsor | Ashutosh Kumar Tewari |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PHASE1)
- Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer (PHASE1)
- Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PGV-001 CI brief — competitive landscape report
- PGV-001 updates RSS · CI watch RSS
- Ashutosh Kumar Tewari portfolio CI